Home

Warfarin vitamin K antagonist

Vitamin K Tablets MYPROTEIN

lookfantastic Continues To Bring The Best Of Beauty Direct To Your Door. Our Delivery Service Remains Unaffected - Shop Bestselling Beauty At lookfantastic Toda Low Prices on Vitamin D Vitamin K. Free UK Delivery on Eligible Order Warfarin and other vitamin K antagonists (VKAs, also called coumarins; eg, acenocoumarol, phenprocoumon, fluindione) are used in a variety of clinical settings. Their use is challenging because their therapeutic range is narrow and dosing is affected by many factors including genetic variation, drug interactions, and diet

Free Worldwide Delivery · Great Prices, Best Brands · Official Sit

Myvitamins Vitamin K -LOOKFANTASTI

  1. k antagonist. STUDY. Flashcards. Learn. Write. Spell. Test. PLAY. Match. Gravity. Created by. Duncanmwangi. Coumadin. Terms in this set (10) Warfarin - Uses-Reduce incidence of thromboembolism • Prosthetic heart valves • Atrial fibrillation-Long-term prophylaxis & treatmen
  2. g treatment with vita
  3. K antagonist (VKA) therapy with warfarin 10 mg daily for the first 2 days followed by dosing based on international normalized ratio (INR) measurements rather than starting with the estimated maintenance dose (Grade 2C). 2.2
  4. K antagonist but itʼs really not antagonizing vita
  5. K. It's important to be consistent in how much vita

They were reporting relationships between non-vitamin K antagonist oral anticoagulants and warfarin in subjects with atrial fibrillation and liver disease. Odds ratio (OR) with 95% confidence intervals (CIs) was calculated to evaluate the prognostic role of the efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with. Severe deficiency of vitamin K-dependent proteins in patients not maintained on vitamin K antagonists is most commonly associated with poisoning by or surreptitious ingestion of warfarin, warfarin-like anticoagulants, or potent rodenticides (superwarfarins), such as brodifacoum. Serious bleeding manifestations are common Warfarin is a vitamin K antagonist. It prevents the liver from utilizing vitamin K to make clotting factors II, VII, IX and X. The patient is usually under the care of an anticoagulation clinic, although some patients are monitored by their general medical practitioner Background Several studies have investigated the effect of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with cancer, but the results remain controversial. Therefore, we conducted a meta-analysis to compare the efficacy and safety of NOACs versus warfarin Warfarin is a vitamin K antagonist (fig 1) and a coumarin (more accurately 4-hydroxycoumarin) derivative

Treatment recommendations guiding clinical practice on optimal OAC agent selection in this population are lacking. This study aimed to investigate the comparative effectiveness and safety of non-vitamin K antagonist OAC (NOAC) versus warfarin in patients with AF sustaining an intracerebral hemorrhage Acetaminophen: May enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days

Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation with Coronary or Peripheral Artery Disease. Zhang H(1), Xue Z(2), Yi D(3), Li X(1), Tan Y(1), Li J(1). Author information: (1)Department of Cardiovascular Medicine, Xiangdong Hospital Hunan normal University Selected Anticoagulants (Vitamin K antagonists)/Vitamin K Interactions . This information is generalized and not intended as specific medical advice

Background: Anticoagulant treatment with vitamin K antagonists (VKAs) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation (AF) for many decades. A new class of anticoagulants, the factor Xa inhibitors, appear to have several pharmacological and practical advantages over VKAs Several randomized trials and real-world studies have reported the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in Asian patients with atrial fibrillation; and therefore, this meta-analysis was aimed to compare the effects of NOACs with warfarin for atrial fibrillation stroke prevention in Asians Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans. Diphenadione. Not Annotated. Tioclomarol. Not Annotated. 4-hydroxycoumarin. Not Available. (R)-warfarin. Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways is warfarin a vitamin k agonist or antagonist. antagonist. what are the vitamin k clotting factors. II vii ix x. indication for use of warfarin. deep vein thromosis pulmonary embolism atrial fibrillation. precautions with warfarin The search terms restricted to the title/abstract were included: (atrial fibrillation OR atrial flutter) AND (non-vitaminK antagonist oral anticoagulants OR direct oral anticoagulants OR dabigatran OR rivaroxaban OR apixaban OR edoxaban) AND (vitamin-K antagonists OR warfarin). No language restriction was applied in the search

Vitamin D Vitamin

Importance: Current guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data regarding warfarin sodium use compared with NOAC use in patients with AF with a history of intracranial hemorrhage (ICH) are limited Warfarin sodium is a vitamin K antagonist indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism ( 1) Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement ( 1). For a patient who is taking warfarin or another vitamin K antagonist, with an INR below 4, treat without interrupting their anticoagulant medication. (Strong recommendation; low quality evidence) This recommendation is based on the available evidence and extensive clinical experience. It should be considered a strong recommendation, because of. Vitamin K antagonists (VKAs) such as warfarin inhibit the enzyme vitamin K epoxide reductase and consequently the recycling of inactive vitamin K epoxide back to its active, reduced form [].Vitamin K in its active form is required for the synthesis of various clotting factors (II, VII, IX and X) involved in the coagulation cascade (as well as the anti-clotting proteins C and S); and thus, VKAs.

antithrombotics - Pharmacology 1 with Lynch at Eastern

Vitamin K antagonist anticoagulants (VKAs), such as warfarin and acenocoumarol, act as anticoagulants through inhibition of vitamin K-dependent blood coagulation proteins. VKAs likely also affect the functioning of other vitamin K-dependent proteins such as MGP Warfarin, a vitamin K antagonist, is used to prevent thrombotic events in conditions such as atrial fibrillation (AF). More than 30 million warfarin prescriptions are dispensed annually, but despite the widespread use, it has many limitations What are vitamin K antagonists? A vitamin K antagonist (VKA) is a special blood thinner. VKAs prevent blood clots by decreasing the action of vitamin K. Among VKAs, coumarins are the most commonly used. And among coumarins, warfarin (sold under the brand name Coumadin and Jantoven) is the most popular. The interfering action, however, goes both. How vitamin K antagonists (warfarin) cause anticoagulation. Warfarin prevents the formation of a blood clots in patients by reducing the production of factors II, VII, IX, and X, and the anticoagulant proteins C and S by the liver. These factors are involved in the body's natural clotting process

Eliquis®| Pfizer India | Apixaban | Dosing and Switching

The reductive branch of the cycle in hepatocytes is predominantly catalyzed by the vitamin K epoxide reductase (VKOR) encoded by VKORC1. 6,7 The electrons to reduce vitamin K are supplied by the reduced dithiol motif within thioredoxin-like proteins. 8-11 Vitamin K antagonists such as warfarin inhibit VKOR to disrupt the vitamin K cycle. As VKA effect increases, hepatic synthesis of vitamin K-dependent factor X decreases. Therapeutic warfarin is associated with factor X activity of 20% to 40%. 8 In one study, chromogenic factor X levels of less than or equal to 45% had 63.2% sensitivity, 80% specificity, 93.5% positive predictive value, and 32.3% negative predictive value for. Warfarin is a vitamin K antagonist that is the most commonly prescribed anticoagulant and continued use is anticipated even with the new anticoagulants. It is well known that warfarin has a narrow therapeutic range, potential life-threatening side effects and is known for multiple drug-drug, drug-disease, and drug-food interactions Warfarin acts as a Vitamin K antagonist, that is it blocks the action of vitamin K epoxide reductase. Vitamins K 1 and K 2. This vitamin is found in brassicas, spinach, parsley, and other green vegetables, avocado pairs are also rich in Vitamin K 1. For Vitamin K 2, n signifies a number of five-carbon side chain units, hence MK-n. Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

UpToDat

Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J. Thromb. Thrombolysis31(3), 249-258 (2011). Crowther MA, Ageno W, Garcia D et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial Warfarin is a traditional oral anticoagulant for preventing thrombotic events in patients with atrial fibrillation (AF) and venous thromboembolism. Along with the widespread clinical use, the potential association between warfarin use and fracture risk have been addressed gradually. Non-vitamin K antagonist oral anticoagulants (NOACs), targeting thrombin or Xa factor, have been recommended as. Introduction. Pooled results from clinical trials showed that treatment with non-vitamin K antagonist oral anticoagulants (NOACs) significantly increased the risk of upper gastrointestinal bleeding (UGIB) compared with warfarin.1 Proton pump inhibitors (PPIs) reduce gastric acid production and prevent ulcer recurrence.2 In patients on aspirin treatment, which increases the risk of GIB,3 PPIs. Warfarin is a blood thinner that can be more effective when restricting foods that are vitamin K-rich. Examples of these include broccoli and asparagus. Learn more about foods to avoid on the. Comparison of action mechanisms between warfarin and non-vitamin K antagonists. Compared to warfarin, the pharmacokinetic advantages of NOACs include a more rapid onset (time to peak: 1 to 3 h), shorter elimination half-life (5 to 15 h), lower predisposition to food and drug interaction (do not require restriction on vitamin K-containing food.

Warfarin and Vascular Calcificatio

  1. K antagonist oral anticoagulants (NOACs) The NOACs have fewer identified drug interactions compared to warfarin. However, they should either not be given, or should be co-ad
  2. K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015;46:2555-2561
  3. K antagonists such as warfarin and phenprocoumon. Non-vita

Vitamin K Antagonist - an overview ScienceDirect Topic

A vitamin K antagonist is a type of medication that opposes the effects of vitamin K in the body. These medications are often used as anticoagulants, which means that they are given to patients in order to decrease the ability of the blood to clot. The most commonly used pharmaceutical agent in this class of drugs is warfarin Phase III randomized controlled trials for non-vitamin K antagonist anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF) have demonstrated, at a minimum, their. Direct oral anticoagulants (DOACs) are not only increasingly being used for the initial stroke prevention therapy but progressively also substitute vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (AF). DOACs have been compared regarding therapeutic efficacy and adverse outcomes to warfarin in several pivotal studies and showed non-inferiority in terms of. Warfarin was discontinued on day 5 (ie 3 days after favipiravir initiation), but INR increased to 4.63 on day 6, and the patient required vitamin K2 administration. Although warfarin was resumed at half the initial dose (1.0 mg/day) on day 9, the INR increased. Concomitantly, dexamethasone and vonoprazan were discontinued, but favipiravir was not

warfarin therapy 5 days prior to surgery For patient who have had their warfarin therapy stopped and the INR is still 1.5 or higher 1 to 2 days prior to surgery it is recommended to administer vitamin K 2.5mg PO ***10mg vitamin K IV infusion dilute in 25ml NS give over 15 minutes*** Reference: Chest. Vol 133. number 6. June 2008 p.72s-73s,175s-176 The first randomised controlled trial comparing warfarin and aspirin to prevent thromboembolic complications in AF patients was published in 1989 [5]. Five years later, the first study of a vitamin K antagonist (VKA) in AF patients with an explicit focus on very old patients was published [6] Vitamin K Antagonist. Agents that inhibit the intrahepatic intercoversion of Vitamin K to its reduced form; In the absence of Vitamin K Clotting Factors/proteins are not activated and Clotting Cascade does not occur; Warfarin is the most commonly used Vitamin K Antagonist; Other Vitamin K Antagonists include Dicumarol, phenprocoumon and. Atrial fibrillation (AF) increases a patient's stroke risk four- to five-fold. Anticoagulation with the vitamin K antagonist (VKA) warfarin reduces the risk of stroke by 67%, but warfarin carries a significant risk of major bleeding and has unpredictable pharmacodynamics with a narrow therapeutic window, necessitating frequent monitoring of its anticoagulant effect. The non-vitamin K.

Warfarin and Vitamin K Michigan Medicin

PPT - Vitamin K & Coagulation PowerPoint PresentationChest radiograph showing fluffy opacities in the lung

To compare the risk of diabetes development in patients with atrial fibrillation (AF) treated with non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin. Materials and Methods. We conducted a nationwide retrospective cohort study using Taiwan's National Health Insurance Research Database Purpose Both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) have pleiotropic effects including anti-inflammatory and anti-fibrotic properties. This study aims to explore whether arrhythmia recurrence after AF ablation is influenced by the choice of oral anticoagulant. Methods We retrospectively studied all patients who underwent primary AF ablation between 2011 and 2017 and. Radio- Warfarin (Cumarin, Coumadin) embryopathy is caused graphs showed abnormal ossification of the cervical vertebral bod- by maternal ingestion of the vitamin K antagonist anti- ies and instability of C1±2 (Fig. 3). His neck was immobilized with a coagulant in the first trimester of pregnancy Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). American Journal of Cardiology. 2017 May 15;119(10):1590-1595 Choice of nonvitamin K antagonist oral anticoagulants was independently associated with 20-day or shorter hospitalization (OR 2·46, 95% CI 1·87-3·24).Conclusions Warfarin use at acute.

Warfarin (Vitamin K Antagonists) Pharmacology - The

  1. K antagonist oral anticoagulants (NOACs) have pleiotropic effects including anti-inflammatory and anti-fibrotic properties. This study aims to explore whether arrhythmia recurrence after AF ablation is influenced by the choice of oral anticoagulant
  2. K antagonist oral anticoagulants (NOACs) are now recommended as first-line therapy, in preference to warfarin, as thromboembolism prophylaxis for individuals with nonvalvular atrial fibrillation (AF). However, that guideline is based on trials that excluded patients with postoperative AF, so the optimal oral anticoagulant for that.
  3. K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510.doi:10.1136/bmj.j51
  4. -K antagonist oral anticoagulants versus vita
  5. K antagonist under development for use as an anticoagulant. A Phase II/III clinical trial in 607 people, comparing it to the established vita

Although this supplemental daily amount is probably beneficial in preventing vitamin K deficiency, it may be excessive for patients taking vitamin K antagonists, such as warfarin, and jeopardize. ORLANDO -- Non-vitamin K antagonist oral anticoagulants (NOACs) were associated with fewer adverse bone outcomes compared to warfarin among older patients with atrial fibrillation, a retrospective. Non-vitamin K antagonist oral anticoagulants (NOACs) were in pivotal randomised controlled trials non-inferior to warfarin for stroke prevention in atrial fibrillation (AF), but the mean time in therapeutic range (TTR) of 55%-65% for warfarin in these studies was substantially lower than the ≥70% recommended in the European AF guidelines Warfarin used to be the most common OAC worldwide; however, warfarin exhibited a higher bleeding tendency in Asians. 10 Due to their non-inferior efficacy, better safety, and easier administration without the need for frequent blood tests, non-vitamin K antagonist OACs (NOACs) are currently considered first-line treatment for AF patients. 11. Non-Vitamin K antagonist oral anticoagulants (NOAC) are now widely used in patients with non-valvular atrial fibrillation (AF) and for the treatment and prevention of venous thromboembolism (VTE) in NSW Health facilities

Vitamin K Antagonist Oral Anticoagulants Clinical Pathway 3 | P a g e Table 1: Adult Target INR Ranges Based Upon Indication Warfarin is widely used for several off-labeled indications that are not listed below. This might be supported by weak evidence KEYWORDS: anticoagulation † quality † vitamin K antagonist † warfarin Oral anticoagulation therapy with the vitamin K antagonists (VKA), particularly warfarin, which is the most commonly used VKA, con-tinues to increase worldwide due to the aging population and its efficacy in preventing stroke in patients with atrial fibrillation or.

Non-Vitamin K Antagonist Oral Anticoagulants Versus

  1. K antagonist (Warfarin) therapy? What problem was this research addressing? Individuals with atrial fibrillation, heart valve disease, or other cardiac conditions are at heightened risk of blood clots for
  2. K antagonist (warfarin). Evidence is based on recommendations from the Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Clinical Practice Guidelines. It provides recommendations for how to initiate, dose adjust and monitor warfarin therapy in the ambulatory setting
  3. K (phytonadione) provides the substrate required to synthesize coagulation factors inhibited by warfarin and other VKA [1-3]. The main limitation of vita
  4. K antagonists (e.g., warfarin [Coumadin]), unfractionated heparin, low-molecular-weight heparin (LMWH), and direct oral anticoagulants are commonl
  5. K) Dosing Guidelines INR > 9.0, No significant bleeding Repeat INR; hold warfarin. Monitor INR every 12-24 hours. Consider oral phytonadione at a dose of 2.5 to 5 mg (INR reduction expected to occur within 24 hours). Resume warfarin at a lower dose when the INR approaches the therapeutic range. Repeat INR; hold.
  6. K are green leafy vegetables such as kale, collard greens, broccoli, spinach, cabbage, and lettuce. Other foods that could affect warfarin may include beef liver or other animal liver products. Vita

Video: Vitamin K Antagonists - an overview ScienceDirect Topic

Vitamin K antagonist - Wikipedi

  1. K2 and Warfarin (Coumadin) Vita
  2. K antagonist therapy, most commonly warfarin in the United States, is prescribed for stroke prevention in patients with atrial fibrillation and for venous thromboembolism prevention in.
  3. K antagonists (VKA), particularly warfarin, which is the most commonly used VKA, continues to increase worldwide due to the aging population and its.
  4. K antagonists - ATC Code: B01AA - Sub categories: Dicoumarol, Phenindione, Warfarin
  5. K Antagonist Oral Anticoagulants in Clinical Practice : Millions of patients worldwide are prescribed oral anticoagulation therapy. The indications for oral anticoagulation include stroke prevention in nonvalvular atrial fibrillation with CHA 2 DS 2-VASc score ≥2 in men or ≥3 in women,.
  6. -K antagonist (VKA) patients undergoing invasive procedures and involves complex risk assessment in order to prevent thromboembolic and bleeding outcomes. Our aim was to assess guideline compliance and identify factors associated with bridging and especially, non-compliant bridging. A retrospective review of 256 patient records in 13 Dutch hospitals.

Vitamin K can be inhibited by the anticoagulant drug warfarin, which acts as an antagonist for vitamin K. Warfarin is used in medicine for those at high risk of thromboembolism to prevent the coagulation cascade by reducing vitamin K dependent synthesis of coagulation factors Vitamin K antagonists, such as warfarin, have been used for years for prevention of stroke in patients with atrial fibrillation. However, the use of these drugs has been limited by interpatient and intrapatient variability, the need for laboratory monitoring, and important interactions with food and other drugs.1 During the last few years, non-vitamin K antagonist oral anticoagulants (NOACs. Purpose Both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) have pleiotropic effects including anti-inflammatory and anti-fibrotic properties. This study aims to explore whether. Cardiology Today | Vitamin K antagonist exposure did not influence the outcome of two different doses of dabigatran when compared with warfarin among patients with atrial fibrillation, results. The meta-analysis indicated that low-intensity warfarin therapy (INR target of 1.5-2.5) can achieve reduced hemorrhage without increasing thromboembolism for Asian patients with NVAF taking warfarin [6-9]. Recently, non-vitamin K antagonist oral anticoagulants (NOACs) have been demonstrated to be effective and safe for prevention of.

INTRODUCTION. Between 2010 and 2015, the non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban were approved in the United States for reduction of the risk of stroke and systemic embolic event (SEE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of acute venous thromboembolism (VTE) Vitamin K antagonists. Vitamin K is essential for the synthesis of multiple factors in the coagulation cascade: Factors II (prothrombin), VII, IX and X, as well as protein C and protein S 1. Antagonists of vitamin K have been used as anticoagulants for over 50 years. Warfarin, a synthetic derivative of coumarin, is the most commonly used VKA, 1. warfarin and selumetinib both increase anticoagulation. Modify Therapy/Monitor Closely. An increased risk of bleeding may occur in patients taking a vitamin-K antagonist or an antiplatelet agent with selumetinib. Monitor for bleeding and INR or PT in patients coadministered a vitamin-K antagonist or an antiplatelet agent with selumetinib Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016; 353:i3189. Crossref | PubMe Vitamin K1 is reduced to vitamin KH2. The major warfarin-sensitive enzyme in this reaction is the vitamin K Outpatient Management of Oral Vitamin K Antagonist Therapy: Defining and.

MOA Kcentra® | (Prothrombin complex concentrate [human])

Warfarin, Vitamin k antagonist Flashcards Quizle

Jones D, Wright P, Alizadeh M, Fhadil S, Rathod K, Guttmann O, et al. The use of novel oral anti-coagulant's (NOAC) compared to vitamin K antagonists (Warfarin) in patients with left ventricular thrombus after acute myocardial infarction (AMI). Eur Heart J Cardiovasc Pharmacother. 2020. Epub 2020/07/31. pmid:32730627. View Articl Radio- Warfarin (Cumarin, Coumadin) embryopathy is caused graphs showed abnormal ossification of the cervical vertebral bod- by maternal ingestion of the vitamin K antagonist anti- ies and instability of C1±2 (Fig. 3). His neck was immobilized with a coagulant in the first trimester of pregnancy Shortly thereafter, the role of vitamin K as a cofactor to activate MGP was shown by inhibition of MGP function using warfarin, a vitamin K-antagonist 40. The role of the Gla-domain in inhibiting vascular calcification was revealed by mutagenesis of the protein bound glutamate residues, resulting in non-functional MGP 41 Warfarin is an endogenous vitamin K antagonist; therefore, patients who are taking warfarin must be prohibited from taking vitamin K. Vitamin K is an essential cofactor required for the ɤ-carboxylation of vitamin K-dependent proteins including coagulation factors, osteocalcin (OC), matrix Gla protein (MGP), and the growth arrest-specific 6. Warfarin has been used for six decades but in the last 8 years its use has been gradually replaced by non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran, rivaroxaban, and apixaban. Unlike warfarin, these drugs have set doses and do not generally require regular international normalisation ratio blood test monitoring.

Having a cheat day where you eat a large amount of vitamin K, like a spinach salad, could be extremely harmful. This is a guide to which foods you can eat and in what amounts. Exact amounts will depend on your dosage of Warfarin. Listed below are foods low in vitamin K presented by food group with sample serving sizes and amounts of vitamin K Atrial fibrillation is a common arrhythmia that increases the risk of stroke. 1 Vitamin K antagonist therapy is more effective than aspirin for the prevention of stroke in patients with atrial. Currently, four non-VKA [vitamin K antagonist] oral anticoagulant (NOAC) drugs are available on the UK market as alternatives to warfarin: dabigatran, rivaroxaban, apixaban and edoxaban